Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a novel BRCAness score that predicts response to PARP inhibitors

12 Nov 2022

Abstract excerpt

BACKGROUND: BRCAness is a characteristic feature of homologous recombination deficiency (HRD) mimicking BRCA gene mutation in breast cancer. We hypothesized that a measure to quantify BRCAness that causes synthetic lethality in BRCA mutated tumors will identify responders to PARP inhibitors. METHODS: A total of 6753 breast cancer patients from 3 large independent cohorts were analyzed. A score was generated by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36371386
DOI: 10.1186/s40364-022-00427-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a novel BRCAness score that predicts response to PARP inhibitorsPMID 36371386Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signaturesSemantic proximity Read ↗

Homologous repair deficiency score for identifying breast cancers with defective DNA damage responseSemantic proximity Read ↗

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Semantic proximity Read ↗

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

A multiomics signature highlights alterations underlying homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficienciesSemantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.